Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy.

Baker DL, Peng K, Cheu M, Fischer SK.

Curr Med Res Opin. 2014 May;30(5):913-22. doi: 10.1185/03007995.2013.877435. Epub 2014 Jan 24.

PMID:
24354863
2.

Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.

Kornmann O, Watz H, Fuhr R, Krug N, Erpenbeck VJ, Kaiser G.

Pulm Pharmacol Ther. 2014 Aug;28(2):149-53. doi: 10.1016/j.pupt.2014.03.003. Epub 2014 Mar 18.

4.

Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.

Lowe PJ, Georgiou P, Canvin J.

Regul Toxicol Pharmacol. 2015 Feb;71(1):68-77. doi: 10.1016/j.yrtph.2014.12.002. Epub 2014 Dec 8.

5.

Re: Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. Curr Med Res Opin 2014;30:913-22.

Strohner P, Becher G.

Curr Med Res Opin. 2014 Oct;30(10):1923-5. doi: 10.1185/03007995.2014.933099. Epub 2014 Jul 7. No abstract available.

PMID:
24914579
6.

Monitoring free serum IgE in severe asthma patients treated with omalizumab.

Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R.

Respir Med. 2012 Nov;106(11):1494-500. doi: 10.1016/j.rmed.2012.07.010. Epub 2012 Aug 11.

7.

Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22.

Baker DL, Peng K, Cheu M, Fischer SK.

Curr Med Res Opin. 2014 Oct;30(10):1927-9. doi: 10.1185/03007995.2014.938150. Epub 2014 Jul 7. No abstract available.

PMID:
24960148
8.

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.

Lowe PJ, Tannenbaum S, Gautier A, Jimenez P.

Br J Clin Pharmacol. 2009 Jul;68(1):61-76. doi: 10.1111/j.1365-2125.2009.03401.x.

9.
10.

Plasmapheresis prior to omalizumab administration in a 15-year-old boy with severe asthma and very high IgE levels: sustained effect over 2 years.

Kerzel S, Zemlin M, Rogosch T, Ollert M, Renz H, Klaus G, Maier RF.

Klin Padiatr. 2011 Nov;223(6):356-9. doi: 10.1055/s-0031-1287824. Epub 2011 Oct 19.

PMID:
22012605
11.

Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.

Zielen S, Lieb A, De La Motte S, Wagner F, de Monchy J, Fuhr R, Munzu C, Koehne-Voss S, Rivière GJ, Kaiser G, Erpenbeck VJ.

Int Arch Allergy Immunol. 2013;160(1):102-10. doi: 10.1159/000339243. Epub 2012 Aug 28.

PMID:
22948442
12.

Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.

Zhu R, Zheng Y, Putnam WS, Visich J, Eisner MD, Matthews JG, Rosen KE, D'Argenio DZ.

AAPS J. 2013 Apr;15(2):559-70. doi: 10.1208/s12248-013-9463-9. Epub 2013 Feb 15.

13.

Development of assay for determining free IgE levels in serum from patients treated with omalizumab.

Ito R, Gon Y, Nunomura S, Atsuta R, Harada N, Hattori T, Maruoka S, Okayama Y, Ra C, Hashimoto S.

Allergol Int. 2014 May;63 Suppl 1:37-47. doi: 10.2332/allergolint.13-OA-0643.

14.

Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.

Steiss JO, Schmidt A, Nährlich L, Zimmer KP, Rudloff S.

Allergy Asthma Proc. 2012 Jan-Feb;33(1):77-81. doi: 10.2500/aap.2012.33.3500.

PMID:
22370532
15.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
16.

Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents.

Sorkness CA, Wildfire JJ, Calatroni A, Mitchell HE, Busse WW, O'Connor GT, Pongracic JA, Ross K, Gill MA, Kattan M, Morgan WJ, Teach SJ, Gergen PJ, Liu AH, Szefler SJ.

J Allergy Clin Immunol Pract. 2013 Mar;1(2):163-71. doi: 10.1016/j.jaip.2013.01.011. Epub 2013 Feb 26.

17.

Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.

Dal Negro RW, Guerriero M, Micheletto C, Tognella S, Visconti M.

J Asthma. 2011 Jun;48(5):437-41. doi: 10.3109/02770903.2011.578316.

PMID:
21599560
18.

Monitoring of omalizumab therapy by measuring free IgE using a bedside immunoassay.

Steiss JO, Schmidt A, Rudloff S.

Clin Lab. 2015;61(1-2):31-7.

PMID:
25807635
19.
20.

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.

Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ.

J Allergy Clin Immunol. 2009 Jan;123(1):107-113.e3. doi: 10.1016/j.jaci.2008.09.050.

PMID:
19130931

Supplemental Content

Support Center